General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
20-60
Half-Life (Normalesrd) Hours
4-8/19
Plasma Protein Binding %
74-94
Volume Of Distribution L/Kg
0.17-0.5
Dose For Normal Renal Function
35-100 mg/m2 q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [B]
References
Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet. 1987; 12: 223-52. [PMID: 3297462] / McLeod HL, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv. 1993; 17: 253-68. [PMID: 8137343] / Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology,pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmaco-therapy. 1984; 4: 61-73. [PMID: 6326063] / Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol. 1994; 34 Suppl: S76-83. [PMID: 8070032]